Arg-Gly-Asp-Ser

  Cat. No.:  DC9487   Featured
Chemical Structure
91037-65-9
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS
Cas No.: 91037-65-9
Chemical Name: Arg-gly-asp-ser
Synonyms: L-Serine,L-arginylglycyl-L-a-aspartyl-;Arg-Gly-Asp-Ser;arginyl-glycyl-aspartyl-serine;H-Arg-Gly-Asp-Ser-OH;RGDS;RGDS peptide;2ACOH 2H2O;Arg-Gly-Asp-Ser-OH;fibronectin active fragment;FIBRONECTIN INHIBITOR;L-ARG-GLY-ASP-SER;L-Arg-Gly-L-Asp-L-Ser-OH;RGDS 1;Palmitoyl Oligopertide;Fibronectin tetrapeptide;C15H27N7O8;L-Arginylglycyl-L-alpha-aspartyl-L-serine;L-Serine, L-arginylglycyl-L-alpha-aspartyl-;L-Serine, N-(N-(N-L-arginylglycyl)-L-alpha-aspartyl)-;AK163508;3-[(S)-2-((S)-2-Amino-5-guanidino-pentanoylamino)-acetylamino]-N-(1-carboxy-2-hydroxy-ethyl)-succinamic acid;BDBM50241180;3450AH;AKO;L-Arginylglycyl-L-α-aspartyl-L-serine (ACI);L-Serine, N-[N-(N-L-arginylglycyl)-L-α-aspartyl]- (ZCI);102: PN: WO2008113030 SEQID: 103 unclaimed sequence;10: PN: JP2003089648 SEQID: 11 unclaimed;10: PN: WO03099465 SEQID: 11 claimed protein;10: PN: WO2020081717 SEQID: 10 claimed protein;110: PN: US20100136614 SEQID: 111 unclaimed sequence;11: PN: US20050142094 SEQID: 11 unclaimed sequence;11: PN: WO2013007839 SEQID: 52 claimed protein;12: PN: JP2004000070 SEQID: 14 unclaimed protein;12: PN: WO0044808 TABLE: 4 unclaimed sequence;12: PN: WO03089607 SEQID: 12 claimed sequence;13: PN: US20100028387 SEQID: 13 claimed protein;13: PN: US20140004158 SEQID: 14 claimed sequence;13: PN: US6111069 SEQID: 6 claimed protein;13: PN: WO2017072759 SEQID: 13 claimed sequence;14: PN: JP2003210166 SEQID: 14 claimed protein;14: PN: JP2004049921 SEQID: 14 unclaimed protein;16: PN: EP3415165 SEQID: 16 claimed protein;16: PN: KR20140027031 SEQID: 17 claimed protein;16: PN: WO0105991 SEQID: 17 unclaimed sequence;16: PN: WO2022027020 PAGE: 57 claimed sequence;172: PN: US20080107614 SEQID: 134 unclaimed sequence;18: PN: US20040228913 SEQID: 11 claimed sequence;18: PN: US6147189 SEQID: 6 claimed protein;18: PN: WO2011163398 SEQID: 15 unclaimed protein;1: PN: JP2002369878 SEQID: 11 unclaimed sequence;1: PN: JP2007230891 SEQID: 1 claimed protein;1: PN: JP2008195682 SEQID: 1 unclaimed protein;1: PN: JP2008195683 SEQID: 1 unclaimed protein;1: PN: JP2023038840 SEQID: 1 claimed sequence;1: PN: KR20150027940 SEQID: 2 claimed sequence;1: PN: US20040023391 PAGE: 9 claimed protein;1: PN: US20150064143 SEQID: 1 claimed sequence;1: PN: US6013628 SEQID: 16 unclaimed protein;1: PN: US6043216 SEQID: 1 claimed sequence;1: PN: WO0178529 PAGE: 26 unclaimed sequence;1: PN: WO0187071 SEQID: 2 unclaimed sequence;1: PN: WO2012124998 SEQID: 3 claimed protein;1: PN: WO2012135813 PAGE: 8 claimed protein;1: PN: WO2014172355 SEQID: 1 claimed protein;1: PN: WO2017036533 SEQID: 1 claimed protein;1: PN: WO2017040335 SEQID: 210 claimed sequence;1: PN: WO2017059312 SEQID: 1 claimed sequence;1: PN: WO2017160862 SEQID: 7 claimed protein;1: PN: WO2018201051 SEQID: 383 claimed protein;1: PN: WO2019104154 SEQID: 1 claimed protein;1: PN: WO2020097235 SEQID: 31 claimed sequence;1: PN: WO2022234536 SEQID: 1 claime...
SMILES: [C@@H](CC(=O)O)(NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)O
Formula: C15H27N7O8
M.Wt: 433.416982889175
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9.
In Vivo: Arg-Gly-Asp-Ser (2.5 or 5 mg/kg, 1 h before LPS) significantly inhibits LPS-induced MMP-9 activity in BAL fluid 4 h post-LPS. Arg-Gly-Asp-Ser (1, 2.5 or 5 mg/kg, i.p.) administers 1 h before LPS inhibited LPS-induced increases in TNF-α and MIP-2 levels in BAL fluid at 4 h post-LPS[2]. Arg-Gly-Asp-Ser peptide significantly reduces tumor necrosis factor (TNF)-α and macrophage inflammatory protein (MIP)-2 production, and decreases myeloperoxidase (MPO) and NF-κB activity[3].
In Vitro: The Arg-Gly-Asp-Ser-modified surface causes up-regulation of αvβ3 integrin. Attachment to the Arg-Gly-Asp-Ser-treated membrane completely abolishes apoptosis induced by staurosporine, the Ca2+·Pi ion pair, and sodium nitroprusside. Arg-Gly-Asp-Ser-dependent resistance to apoptosis is eliminated, when the activity of the phosphatidylinositol 3-kinase pathway is inhibited[1]. Arg-Gly-Asp-Ser interacts with survivin, as well as with procaspase-3, -8 and -9. Arg-Gly-Asp-Ser-peptide binding to survivin is found to be specific, at high affinity (Kd 27.5 μM) and locates at the survivin C-terminus. Arg-Gly-Asp-Ser-survivin interaction appears to play a key role, since Arg-Gly-Asp-Ser lost its anti-mitogenic effect in survivin-deprived cells with a specific siRNA[4].
Cell Assay: Cell death is measured using the MTT analysis. This assay is based on the ability of mitochondrial dehydrogenases to oxidize thiazolyl blue (MTT), a tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenylterazolium bromide), to an insoluble blue formazan product. The cells are incubated with the MTT reagent (120 μg/mL) at 37°C for 2 h. After the supernatant is removed, 400 μL of 0.04mol/LHCl in isopropanol is added to each well, and the optical density of the solution is read at 590 nm in an enzyme-linked immunosorbent assay plate reader. As the generation of the blue product is proportional to the dehydrogenase activity, a decrease in the absorbance at 590 nm provides a direct measurement of the number of viable cells. To determine the contribution of the PI3K pathway to inhibition of apoptosis, some cell populations are pretreated with 50 μM LY294002, a PI3K inhibitor. Following this pretreatment, cell death is determined as described above.
Animal Administration: Mice pharyngeal aspiration is performed as described. Animals are anesthetized with a mixture of ketamine and xylazine (45 mg/kg and 8 mg/kg, i.p., respectively). Test solution (30 μL) containing LPS (1.5 mg/kg) is placed posterior in the throat and aspirated into the lungs. Control mice are administrated sterile saline (0.9% NaCl). Animals are administered with Arg-Gly-Asp-Ser or RGES peptide (1, 2.5 or 5 mg/kg, i.p.) once one hour before LPS treatment and sacrificed 4 h post-LPS. Animals are also administered Arg-Gly-Asp-Ser or RGES peptide (5 mg/kg, i.p.) once at different time points (1 h before or 2 h after LPS treatment) and sacrificed 24 h post-LPS. In addition, animals are administered with αvβ3-blocking mAbs, anti-αv, or anti-β3 (5 mg/kg, i.p.) once 1 h before and sacrificed 4 h post-LPS. Animals administered with these mAbs 2 h after LPS treatment are sacrificed 24 h post-LPS
References: [1]. Grigoriou V, et al. Apoptosis and survival of osteoblast-like cells are regulated by surface attachment. J Biol Chem. 2005 Jan 21;280(3):1733-9. [2]. Moon C, et al. Synthetic RGDS peptide attenuates lipopolysaccharide-induced pulmonary inflammation by inhibiting integrin signaled MAP kinase pathways. Respir Res. 2009 Mar 9;10:18. [3]. Yin X, et al. Synthetic RGDS peptide attenuated lipopolysaccharide/D-galactosamine-induced fulminant hepatic failure in mice. J Gastroenterol Hepatol. 2014 Jun;29(6):1308-15. [4]. Aguzzi MS, et al. Intracellular targets of RGDS peptide in melanoma cells. Mol Cancer. 2010 Apr 22;9:84.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
2018-0101
Cat. No. Product name Field of application
DC73236 GSK3335103 GSK3335103 is a highly potent and orally bioavailable nonpeptidic αvβ6 integrin inhibitor with pIC50 of 8.0. GSK3335103 shows high desirable oral pharmacokinetic profiles in rat, dog, and minipig, with low to moderate clearance, moderate volumes of distributio, high to complete oral bioavailabilities and high solubility in all physiological media.
DC40247 THI0019 THI0019 is a potent integrin α4β1 (VLA-4) agonist with an EC50 range of 1-2 μM. THI0019 induces stem/progenitor cells adhesion. THI0019 also regulates adhesion mediated by α4β7, α5β1 and αLβ2.
DC9487 Arg-Gly-Asp-Ser Arg-Gly-Asp-Ser(RGDS peptide) is an integrin binding sequence that inhibits integrin receptor function; decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS
X